Current treatment approaches for infants with malignant central nervous system tumors

Oncologist

Volumn 14, Issue 4, 2009, Pages 433-444

  Lafay Cousin, Lucie ^a,b   Strother, Douglas ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

Brain tumors; Chemotherapy; Infants; Radiation therapy

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; METHOTREXATE; VINCRISTINE;

BRAIN TUMOR; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CHOROID PLEXUS TUMOR; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG MEGADOSE; EPENDYMOMA; FUNCTIONAL STATUS; GLIOMA; HUMAN; INTELLIGENCE; IRRADIATION; MEDULLOBLASTOMA; NERVOUS SYSTEM TUMOR; NEUROECTODERM TUMOR; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; REVIEW; RHABDOID TUMOR; TUMOR LOCALIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA; CEREBELLAR NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHOROID PLEXUS NEOPLASMS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; EPENDYMOMA; EVIDENCE-BASED MEDICINE; GLIOMA; HUMANS; INFANT; MEDULLOBLASTOMA; META-ANALYSIS AS TOPIC; NEUROECTODERMAL TUMORS, PRIMITIVE; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RHABDOID TUMOR; STEM CELL TRANSPLANTATION; SUPRATENTORIAL NEOPLASMS;

EID: 66249140920     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0193     Document Type: Review

References (116)

1. Magnani C, Aareleid T, Viscomi S et al. Variation in survival of children with central nervous system (CNS) malignancies diagnosed in Europe between 1978 and 1992: The EUROCARE study. Eur J Cancer 2001;37:711-721.
2. Duffner PK, Cohen ME, Myers MH et al. Survival of children with brain tumors: SEER Program, 1973-1980. Neurology 1986;36:597-601.
3. Herms JW, Behnke J, Bergmann M et al. Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 1997;19:510-515. (Pubitemid 28099081)
4. Pan E, Pellarin M, Holmes E et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005;11:4733-4740. (Pubitemid 41557192)
5. Duffner PK, Horowitz ME, Krischer JP et al. The treatment of malignant brain tumors in infants and very young children: An update of the Pediatric Oncology Group experience. Neuro Oncol 1999;1:152-161.
6. Suc E, Kalifa C, Brauner R et al. Brain tumours under the age of three. The price of survival. A retrospective study of 20 long-term survivors. Acta Neurochir (Wien) 1990;106:93-98.
7. Fouladi M, Gilger E, Kocak M et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005;23:7152-7160. (Pubitemid 46260302)
8. Walter AW, Mulhern RK, Gajjar A et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol 1999;17:3720-3728.
9. Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol 1997;28:348-354. (Pubitemid 27163672)
10. Packer RJ, Gurney JG, Punyko JA et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: Childhood cancer survivor study. J Clin Oncol 2003;21:3255-3261. (Pubitemid 46606258)
11. Copeland DR, deMoor C, Moore BD 3rd et al. Neurocognitive development of children after a cerebellar tumor in infancy: A longitudinal study. J Clin Oncol 1999;17:3476-3486. (Pubitemid 29517918)
12. Duffner PK, Cohen ME, Voorhess ML et al. Long-term effects of cranial irradiation on endocrine function in children with brain tumors. A prospective study. Cancer 1985;56:2189-2193.
13. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 2001;17:503-511. (Pubitemid 32842704)
14. Peris-Bonet R, Martínez-García C, Lacour B et al. Childhood central nervous system tumours-incidence and survival in Europe (1978-1997): Report from Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2064-2080.
15. Dobbing J, Sands J. Quantitative growth and development of human brain. Arch Dis Child 1973;48:757-767.
16. Marec-Berard P, Jouvet A, Thiesse P et al. Supratentorial embryonal tumors in children under 5 years of age: An SFOP study of treatment with postoperative chemotherapy alone. Med Pediatr Oncol 2002;38:83-90. (Pubitemid 34113436)
17. Chi SN, Gardner SL, Levy AS et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 2004;22:4881-4887. (Pubitemid 46638611)
18. Smith MA, Freidlin B, Ries LA et al. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst 1998;90:1269-1277. (Pubitemid 28433471)
19. Gurney JG, Smith MA, Bunin GR. CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries L, Smith MA, Gurney JG et al., eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, 1999:51-64.
20. Keene D, Lafay-Cousin L, Carret AS et al. The Canadian Pediatric Brain Tumor Consortium national survey of CNS tumors in children under 3 years of age [abstract]. Neuro Oncol 2008;10:416.
21. Rickert CH. Epidemiological features of brain tumors in the first 3 years of life. Childs Nerv Syst 1998;14:547-550. (Pubitemid 28503598)
22. Tomita T, McLone DG. Brain tumors during the first twenty-four months of life. Neurosurgery 1985;17:913-919. (Pubitemid 16178570)
23. Halperin EC, Watson DM, George SL. Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. Cancer 2001;91:1444-1450. (Pubitemid 32319254)
24. Comi AM, Backstrom JW, Burger PC et al. Clinical and neuroradiologic findings in infants with intracranial ependymomas. Pediatric Oncology Group. Pediatr Neurol 1998;18:23-29.
25. Kellie SJ. Chemotherapy of central nervous system tumours in infants. Childs Nerv Syst 1999;15:592-612. (Pubitemid 29493586)
26. van Eys J, Cangir A, Coody D et al. MOPP regimen as primary chemotherapy for brain tumors in infants. J Neurooncol, 1985;3:237-243. (Pubitemid 15229832)
27. Ater JL, van Eys J, Woo SY et al. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J Neurooncol 1997;32:243-252. (Pubitemid 27077975)
28. Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993;328:1725-1731. (Pubitemid 23170121)
29. Geyer JR, Zeltzer PM, Boyett JM et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: A report from the Children's Cancer Group. J Clin Oncol 1994;12:1607-1615. (Pubitemid 24244996)
30. Geyer JR, Finlay JL, Boyett JM et al. Survival of infants with malignant astrocytomas. A Report from the Children's Cancer Group. Cancer 1995;75:1045-1050.
31. Geyer JR, Sposto R, Jennings M et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 2005;23:7621-7631. (Pubitemid 46291826)
32. Grill J, Sainte-Rose C, Jouvet A et al. Treatment of medulloblastoma with postoperative chemotherapy alone: An SFOP prospective trial in young children. Lancet Oncol 2005;6:573-580. (Pubitemid 41051935)
33. White L, Kellie S, Gray E et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: Promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG). J Pediatr Hematol Oncol 1998;20:125-130. (Pubitemid 28185720)
34. Rutkowski S, Bode U, Deinlein F et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005;352:978-986. (Pubitemid 40349500)
35. Mason WP, Grovas A, Halpern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16:210-221. (Pubitemid 28041601)
36. Goldwein JW, Radcliffe J, Johnson J et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys 1996;34:899-904. (Pubitemid 26089229)
37. Ashley D, Merchant T, Zhou T et al. P9934: Systemic chemotherapy, second- look surgery and conformal radiation therapy limited to the posterior fossa and primary site for children >8 months and >3 years with nonmetastatic medulloblastoma: A Children's Oncology Group phase III study [abstract]. Neuro Oncol 2008;10:436.
38. Zeltzer PM, Boyett JM, Finlay JL et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-845. (Pubitemid 29109313)
39. Geyer R, Levy M, Berger MS et al. Infants with medulloblastoma: A single institution review of survival. Neurosurgery 1991;29:707-710; discussion 710-711.
40. Riva D, Giorgi C, Nichelli F et al. Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology 2002;59:48-53. (Pubitemid 34742793)
41. Buizer AI, De Sonneville LM, van den Heuvel-Eibrink MM et al. Visuomotor control in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. J Int Neuropsychol Soc 2005;11:554-565. (Pubitemid 41478988)
42. Buizer AI de Sonneville LM, van den Heuvel-Eibrink MM et al. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: Effect of treatment intensity. Pediatr Blood Cancer 2005;45:281-290. (Pubitemid 41077161)
43. Rutkowski S, Vin Hoff K, Emser A et al. Prognostic factors and survival of young children with medulloblastoma: An international meta-analysis [abstract]. Neuro Oncol 2008;10:437.
44. Lafay-Cousin L, Mabbott D, Hawkins C et al. Medulloblastoma in infants: Report of an institutional review. Neuro Oncol 2004;6:461.
45. Dhall G, Grodman H, Ji L et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer 2008;50:1169-1175.
46. Rutkowski S. Current treatment approaches to early childhood medulloblastoma. Expert Rev Neurother 2006;6:1211-1221. (Pubitemid 44231978)
47. Butler RW, Hill JM, Steinherz PG et al. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol 1994;12:2621-2629. (Pubitemid 24379648)
48. Goldwein JW, Radcliffe J, Packer RJ et al. Results of a pilot study of lowdose craniospinal radiation therapy plus chemotherapy for children younger than 5 years with primitive neuroectodermal tumors. Cancer 1993;71:2647-2652. (Pubitemid 23100504)
49. Dufour C, Couanet D, Figarella-Branger D et al. Sequential high-dose chemotherapy and reduced craniospinal irradiation in young children with metastatic medulloblastoma [abstract]. Neuro Oncol 2008;10:423.
50. Dupuis-Girod S, Hartmann O, Benhamou E et al. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol 1996;27:87-98.
51. Kalifa C, Grill J. The therapy of infantile malignant brain tumors: Current status? J Neurooncol 2005;75:279-285.
52. Ashley D, Lyon N, Bonner M et al. Developmental and functional outcome following postoperative chemotherapy and local conformal radiation in infants with medulloblastoma using a centrally administered phone-based interview technique, initial report: A Children's Oncology Group study [abstract]. Neuro Oncol 2008;10:434.
53. Grotzer MA, von Hoff K, von Bueren AO et al. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91-implications for investigating childhood medulloblastoma. Klin Padiatr 2007;219:312-317. (Pubitemid 350244522)
54. Ellison DW, Onilude OE, Lindsey JC et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005;23:7951-7957. (Pubitemid 46657395)
55. Fernandez-Teijeiro A, Betensky RA, SturlaLMet al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004;22:994-998. (Pubitemid 41095030)
56. Gajjar A, Chintagumpala M, Ashley D et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma- 96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-820. (Pubitemid 44464063)
57. Ullrich NJ, Pomeroy SL. Pediatric brain tumors. Neurol Clin 2003;21:897-913. (Pubitemid 37267796)
58. Li MH, Bouffet E, Hawkins CE et al. Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurg Focus 2005;19:E3.
59. Dirks PB, Harris L, Hoffman HJ et al. Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 1996;29:75-84. (Pubitemid 26193506)
60. Paulino AC, Melian E. Medulloblastoma and supratentorial primitive neuroectodermal tumors: An institutional experience. Cancer 1999;86:142-148. (Pubitemid 29293387)
61. Jakacki RI. Pineal and nonpineal supratentorial primitive neuroectodermal tumors. Childs Nerv Syst 1999;15:586-591. (Pubitemid 29493585)
62. Jakacki RI, Zeltzer PM, Boyett JM et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: A report of the Children's Cancer Group. J Clin Oncol 1995;13:1377-1383.
63. Gilheeney SW, Saad A, Chi S et al. Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol 2008;89:89-95.
64. Hong TS, Mehta MP, Boyett JM et al. Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: A phase III combined modality study. Pediatr Blood Cancer 2005;45:676-682. (Pubitemid 41279359)
65. Fangusaro J, Finlay JL. Radiation therapy approaches do not currently improve overall survival in young children with sPNET as compared to the Head Start I and II experience. Pediatr Blood Cancer 2008;51:149-150.
66. Albright AL, Wisoff JH, Zeltzer P et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr Neurosurg 1995;22:1-7.
67. Timmermann B, Kortmann RD, Kḧl J et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: Results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol 2006;24:1554-1560. (Pubitemid 46638778)
68. Larouche V, Capra M, Huang A et al. Supratentorial primitive neuroectodermal tumors in young children. J Clin Oncol 2006;24:5609; author reply 5609-5610. (Pubitemid 46631342)
69. Pollack IF. Brain tumors in children. N Engl J Med 1994;331:1500-1507. (Pubitemid 24356310)
70. Robertson PL, Zeltzer PM, Boyett JM et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: A report of the Children's Cancer Group. J Neurosurg 1998;88:695-703. (Pubitemid 28145213)
71. Duffner PK, Krischer JP, Sanford RA et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 1998;28:215-222. (Pubitemid 28402001)
72. Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas. Childs Nerv Syst 1999;15:563-570. (Pubitemid 29493582)
73. Grill J, Le Deley MC, Gambarelli D et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: A multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 2001;19:1288-1296. (Pubitemid 32202532)
74. Timmermann B, Kortmann RD, Kḧl J et al. Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: Results of the prospective German brain tumor trials HIT-SKK 87 and 92. Radiother Oncol 2005;77:278-285. (Pubitemid 41785337)
75. Zacharoulis S, Levy A, Chi SN et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 2007;49:34-40. (Pubitemid 46847065)
76. Grundy RG, Wilne SA, Weston CL et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: The UKCCSG/SIOP prospective study. Lancet Oncol 2007;8:696-705. (Pubitemid 47189085)
77. Grundy R. Primary radiotherapy for childhood ependymoma? [author reply]. Lancet Oncol 2007;8:760-761.
78. Merchant TE, Mulhern RK, Krasin MJ et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiationrelated CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 2004;22:3156-3162. (Pubitemid 41103730)
79. Merchant T, Boop F, Laningham F et al. Conformal radiation therapy for pediatric ependymoma: The St. Jude experience [abstract]. Neuro Oncol 2008;10:407.
80. Lefkowitz I, Rorke L, Packer R et al. Atypical teratoid tumor of infancy: Definition of an entity. Ann Neurol 1987;22:448-449.
81. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: Definition of an entity. J Neurosurg 1996;85:56-65. (Pubitemid 26195038)
82. Biegel JA, Tan L, Zhang F et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002;8:3461-3467. (Pubitemid 35340722)
83. Versteege I, Sévenet N, Lange J et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203-206. (Pubitemid 28325977)
84. Strother D. Atypical teratoid rhabdoid tumors of childhood: Diagnosis, treatment and challenges. Expert Rev Anticancer Ther 2005;5:907-915. (Pubitemid 41599964)
85. Squire SE, Chan MD, Marcus KJ. Atypical teratoid/rhabdoid tumor: The controversy behind radiation therapy. J Neurooncol 2007;81:97-111.
86. Tekautz TM, Fuller CE, Blaney S et al. Atypical teratoid/rhabdoid tumors (ATRT): Improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005;23:1491-1499. (Pubitemid 46260037)
87. Hilden JM, Meerbaum S, Burger P et al. Central nervous system atypical teratoid/rhabdoid tumor: Results of therapy in children enrolled in a registry. J Clin Oncol 2004;22:2877-2884. (Pubitemid 41079907)
88. Gardner SL, Asgharzadeh S, Green A et al. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer 2008;51:235-240.
89. Ronghe MD, Moss TH, Lowis SP. Treatment of CNS malignant rhabdoid tumors. Pediatr Blood Cancer 2004;42:254-260. (Pubitemid 38235076)
90. Olson TA, Bayar E, Kosnik E et al. Successful treatment of disseminated central nervous system malignant rhabdoid tumor. J Pediatr Hematol Oncol 1995;17:71-75.
91. Chen ML, McComb JG, Krieger MD. Atypical teratoid/rhabdoid tumors of the central nervous system: Management and outcomes. Neurosurg Focus 2005;18:E8.
92. Lafay-Cousin L, Keene D, Carret AS et al. CNS atypical teratoid rhabdoid tumor (ATRT) in children less than 36 months: A Canadian Pediatric Brain Tumor Consortium (CPBTC) experience [abstract]. Neuro Oncol 2008;10:370.
93. Packer RJ, Biegel JA, Blaney S et al. Atypical teratoid/rhabdoid tumor of the central nervous system: Report on workshop. J Pediatr Hematol Oncol 2002;24:337-342.
94. Reddy AT. Atypical teratoid/rhabdoid tumors of the central nervous system. J Neurooncol 2005;75:309-313. (Pubitemid 43019486)
95. Zimmerman MA, Goumnerova LC, ProctorMet al. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol 2005;72:77-84. (Pubitemid 41149181)
96. Chi S, Fletcher W, Yao X et al. Results from a single-arm, multiinstitutional phase II study of multiagent age-and risk-adapted radiation therapy for children with newly diagnosed CNS atypical teratoid/rhabdoid tumor (DFCI 02-294) [abstract]. Neurosurgery 2008;10:373.
97. Peters O, Heinzelmann B, Marienhagen J et al. German pediatric atypical teratoid/rhabdoid tumors: Interim analysis of the ATRT-CNS pilot study and retrospective analysis [abstract]. Neuro Oncol 2008;10:371.
98. Greenberg ML. Chemotherapy of choroid plexus carcinoma. Childs Nerv Syst 1999;15:571-577. (Pubitemid 29493583)
99. Berger C, Thiesse P, Lellouch-Tubiana A et al. Choroid plexus carcinomas in childhood: Clinical features and prognostic factors. Neurosurgery 1998;42:470-475. (Pubitemid 28128730)
100. Packer RJ, Perilongo G, Johnson D et al. Choroid plexus carcinoma of childhood. Cancer 1992;69:580-585.
101. St Clair SK, Humphreys RP, Pillay PK et al. Current management of choroid plexus carcinoma in children. Pediatr Neurosurg 1991-1992;17:225-233.
102. Wrede B, Liu P, Ater J et al. Second surgery and the prognosis of choroid plexus carcinoma-results of a meta-analysis of individual cases. Anticancer Res 2005;25:4429-4433. (Pubitemid 41729491)
103. Fitzpatrick LK, Aronson LJ, Cohen KJ. Is there a requirement for adjuvant therapy for choroid plexus carcinoma that has been completely resected? J Neurooncol 2002;57:123-126.
104. Wolff JE, Sajedi M, Coppes MJ et al. Radiation therapy and survival in choroid plexus carcinoma. Lancet 1999;353:2126. (Pubitemid 29278485)
105. Wrede B, Liu P, Wolff JE. Chemotherapy improves the survival of patients with choroid plexus carcinoma: A meta-analysis of individual cases with choroid plexus tumors. J Neurooncol 2007;85:345-351. (Pubitemid 350142525)
106. Chow E, Reardon DA, Shah AB et al. Pediatric choroid plexus neoplasms. Int J Radiat Oncol Biol Phys 1999;44:249-254. (Pubitemid 29205019)
107. Eisenberg HM, McComb JG, Lorenzo AV. Cerebrospinal fluid overproduction and hydrocephalus associated with choroid plexus papilloma. J Neurosurg 1974;40:381-385.
108. Kahn EA, Luros JT. Hydrocephalus from overproduction of cerebrospinal fluid, and experiences with other parillomas of the choroid plexus. J Neurosurg 1952;9:59-67.
109. Pencalet P, Sainte-Rose C, Lellouch-Tubiana A et al. Papillomas and carcinomas of the choroid plexus in children. J Neurosurg 1998;88:521-528. (Pubitemid 28114726)
110. Mabbott DJ, Spiegler BJ, Greenberg ML et al. Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood. J Clin Oncol 2005;23:2256-2263. (Pubitemid 46218718)
111. Central Brain Tumor Registry of the United States (CBTRUS). Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Available at http://www.cbtrus.org/reports/reports.html. Accessed March 12, 2009.
112. Dufour C, Grill J, Lellouch-Tubiana A et al. High-grade glioma in children under 5 years of age: A chemotherapy only approach with the BBSFOP protocol. Eur J Cancer 2006;42:2939-2945. (Pubitemid 44667474)
113. Duffner PK, Krischer JP, Burger PC et al. Treatment of infants with malignant gliomas: The Pediatric Oncology Group experience. J Neurooncol 1996;28:245-256. (Pubitemid 26192399)
114. Sanders RP, Kocak M, Burger PC et al. High-grade astrocytoma in very young children. Pediatr Blood Cancer 2007;49:888-893. (Pubitemid 350022440)
115. Gilles FH, Tavaré CJ, Becker LE et al. Pathologist interobserver variability of histologic features in childhood brain tumors: Results from the CCG-945 study. Pediatr Dev Pathol 2008;11:108-117.
116. Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: A historical-and futuristic-perspective. J Neurooncol 2005;75:253-266. (Pubitemid 43023756)